Therapy of lung cancer in China: introducing the special collection-Reference-Cited by-同舟云学术

Therapy of lung cancer in China: introducing the special collection

Published:2021-01 Issue: Volume:13 Page:175883592110381
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Gan Jiadi¹,Fang Wenfeng²,Zhang Li³

Affiliation:

1. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China

2. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, People’s Republic of China

3. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Peoples Republic of China

Funder

Chinese National Natural Science Foundation Project

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/17588359211038199

Reference14 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

3. PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China

4. Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer

5. A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study;Journal of Cancer Research and Clinical Oncology;2023-06-14

2. Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant (L833V/H835L) lung adenocarcinoma patient: a case report;Anti-Cancer Drugs;2023-04-28

3. Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report;Frontiers in Oncology;2022-08-01